Cancer vaccine pp65 - Immunomic Therapeutics/Duke UniversityAlternative Names: CMV pp65-LAMP mRNA-loaded dendritic cells; Cytomegalovirus pp65-LAMP mRNA-loaded dendritic cells; LAMP + pp65 DC
Latest Information Update: 21 Oct 2016
At a glance
- Originator Immunomic Therapeutics
- Developer Duke University Medical Center; Immunomic Therapeutics
- Class Cancer vaccines; Dendritic cell vaccines
- Mechanism of Action Immunostimulants; Interleukin 2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Glioblastoma